Core Viewpoint - The animal health sector experienced a rise of 0.93% on January 16, with leading gains from BioShares, while the overall market indices showed slight declines [1]. Group 1: Market Performance - The Shanghai Composite Index closed at 4101.91, down 0.26% [1]. - The Shenzhen Component Index closed at 14281.08, down 0.18% [1]. Group 2: Individual Stock Performance - BioShares (600201) led the gains with a closing price of 17.61, up 3.53%, and a trading volume of 480,000 shares, amounting to a transaction value of 840 million yuan [1]. - Other notable performers included: - Huisheng Bio (300871) at 26.03, up 1.36%, with a transaction value of 434 million yuan [1]. - Xianfeng Holdings (002141) at 3.76, up 1.35%, with a transaction value of 8.13 million yuan [1]. - Ruipu Bio (300119) at 20.15, up 0.90%, with a transaction value of 110 million yuan [1]. - Shunlian Bio (688098) at 9.60, up 0.63%, with a transaction value of 40.84 million yuan [1]. Group 3: Capital Flow - The animal health sector saw a net inflow of 112 million yuan from institutional investors, while retail investors experienced a net outflow of 68.65 million yuan [2]. - The capital flow for individual stocks showed: - BioShares had a net inflow of 75.95 million yuan from institutional investors [3]. - Huisheng Bio had a net inflow of 19.63 million yuan from institutional investors [3]. - Xianfeng Holdings had a net inflow of 16.40 million yuan from institutional investors [3].

Core Viewpoint - The announcement details the expected daily related transactions for 2026 by Pulaike Biological Engineering Co., Ltd., emphasizing that these transactions are necessary for the company's operations and will not harm the interests of shareholders, particularly minority shareholders [2][3]. Group 1: Daily Related Transactions Overview - The estimated amount for daily related transactions in 2026 is 39.24 million yuan, accounting for 1.49% of the audited net assets for 2024, and does not require shareholder meeting approval [3]. - The board of directors, including independent directors, has reviewed and approved the proposal, confirming that the transactions are fair and reasonable, and will not affect the company's independence or ongoing operations [3][14]. Group 2: Related Parties and Relationships - The related parties include several pet hospitals and clinics, all controlled by a parent company, with the actual controller of Pulaike also controlling these entities, establishing a clear related party relationship [7][11]. - Other related parties include Zhongke Gene and its subsidiaries, which are also under the same actual control as Pulaike, further solidifying the interconnectedness of these entities [9][11]. Group 3: Transaction Details and Pricing Policies - The main content of the daily transactions includes the sale of goods, provision of leasing services, purchase of goods, and acceptance of labor services, with pricing based on market rates or cost-plus methods to ensure fairness [13]. - The transactions are designed to meet the company's operational needs and are executed in accordance with relevant contracts, ensuring that they do not harm the company's interests or financial status [14].

关于预计 2026 年度日常关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 1、2026 年 1 月 15 日，公司第五届董事会第二十二次会议审议通过了《关 于预计 2026 年度日常关联交易的议案》，关联董事张许科先生、秦德超先生、 胡伟先生、宋永军先生、裴莲凤女士、赵锐先生回避表决。 2、公司 2026 年度预计日常关联交易金额 3,924.00 万元，占公司 2024 年度 经审计净资产的 1.49%，在董事会决策权限范围内，无需提交股东会审议。 证券代码：603566 证券简称：普莱柯 公告编号：2026-003 普莱柯生物工程股份有限公司 3、本议案在审议前已经公司独立董事专门会议审议通过。公司独立董事对 本事项发表了书面意见，认为：公司 2026 年度预计日常关联交易符合《中华人 民共和国公司法》《公司章程》等相关规定，公司与关联方之间发生的交易基于 公司经营需要，交易定价公允、合理，日常关联交易额度的预计符合交易双方业 务 ...

Market Overview - The animal health sector experienced a decline of 0.44% on January 14, with Haili Biological leading the drop [1] - The Shanghai Composite Index closed at 4126.09, down 0.31%, while the Shenzhen Component Index closed at 14248.6, up 0.56% [1] Stock Performance - Notable gainers included: - Qudongli (code: 920275) with a closing price of 10.39, up 10.65% on a trading volume of 112,300 shares and a turnover of 118 million yuan [1] - Huisheng Biological (code: 300871) closed at 25.52, up 1.84% with a trading volume of 270,100 shares and a turnover of 696 million yuan [1] - Major decliners included: - Haili Biological (code: 603718) closed at 6.55, down 1.65% with a trading volume of 237,400 shares and a turnover of 157 million yuan [2] - Zhongmu Co., Ltd. (code: 600195) closed at 7.92, down 1.61% with a trading volume of 201,400 shares and a turnover of 161 million yuan [2] Capital Flow - The animal health sector saw a net outflow of 140 million yuan from institutional investors, while retail investors experienced a net inflow of 52.14 million yuan [2] - The detailed capital flow for selected stocks showed: - Huisheng Biological had a net inflow of 23.06 million yuan from institutional investors [3] - ST Green Kang (code: 002868) faced a significant net outflow of 5.87 million yuan from institutional investors [3]

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Core Viewpoint - The approval of a new veterinary drug, a trivalent inactivated vaccine for Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease, represents a significant advancement for the poultry industry, addressing critical diseases that cause substantial economic losses [1] Company Summary - The company,普莱柯 (603566.SH), announced the approval of its wholly-owned subsidiary, 洛阳惠中生物技术有限公司, for a new veterinary drug [1] - The new vaccine is officially registered as of January 12, 2026, under the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] Industry Summary - Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease are major infectious diseases that severely impact the poultry industry, leading to significant economic losses [1] - The new trivalent inactivated vaccine offers several advantages: 1. Utilizes suspension cell culture technology for more controllable and efficient production [1] 2. Achieves high soluble expression of VP2 protein for infectious bursal disease in a baculovirus vector [1] 3. Provides immunity lasting over 4 months and allows for multi-disease prevention with a single injection, reducing stress on chicken populations from frequent vaccinations [1]

关于子公司获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《兽药管理条例》和《兽药注册办法》规定，经农业农村部审查，批准 普莱柯生物工程股份有限公司（以下简称"公司"）全资子公司洛阳惠中生物技 术有限公司等单位联合申报的"鸡新城疫、禽流感（H9 亚型）、传染性法氏囊 病三联灭活疫苗（La Sota 株+SW001 株+VP2 蛋白，悬浮培养）"为新兽药，并 于 2026 年 1 月 12 日公示了核发《新兽药注册证书》（中华人民共和国农业农村 部公告第 987 号）事项。详情如下： 一、新兽药的基本信息 新兽药名称：鸡新城疫、禽流感（H9 亚型）、传染性法氏囊病三联灭活疫 苗（La Sota 株+SW001 株+VP2 蛋白，悬浮培养） 证券代码：603566 证券简称：普莱柯 公告编号：2026-002 普莱柯生物工程股份有限公司 鸡新城疫、禽流感（H9 亚型）、传染性法氏囊病均是严重危害养禽业的重 要传染病之一，给养鸡业造成巨大的经济损失。鸡新城疫、禽流感（H9 亚型）、 传染性法氏囊病三联灭 ...

Core Insights - The animal health sector experienced a rise of 1.09% on January 13, with Huisheng Biological leading the gains [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Stock Performance - Huisheng Biological (300871) closed at 25.06, up 8.39%, with a trading volume of 276,700 shares and a transaction value of 700 million [1] - Other notable performers included: - Qudongli (920275) at 65.6, up 3.99% [1] - Haili Biological (603718) at 6.66, up 1.99% [1] - Xianfeng Holdings (002141) at 3.77, up 1.34% [1] - Shunlian Biological (688098) at 9.78, up 1.03% [1] Capital Flow - The animal health sector saw a net inflow of 34.99 million from institutional investors, while retail investors contributed a net inflow of 30.94 million [2] - However, speculative funds experienced a net outflow of 65.94 million [2] Individual Stock Capital Flow - Major net inflows were observed in: - Biological Shares (600201) with a net inflow of 39.54 million [3] - Jinhe Biological (002688) with a net inflow of 13.45 million [3] - Xianfeng Holdings (002141) with a net inflow of 10.20 million [3] - Conversely, significant net outflows were noted in: - Biological Shares (600201) with a net outflow of 48.25 million from speculative funds [3] - Jinhe Biological (002688) with a net outflow of 1.46 million from retail investors [3]

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for a new veterinary drug, which will enhance its product offerings in the poultry vaccine market [1] Group 1: Product Development - The new veterinary drug is a trivalent inactivated vaccine for preventing Newcastle disease, H9 subtype avian influenza, and infectious bursal disease [1] - The vaccine is characterized by efficient production, high expression, and long-lasting immunity [1] Group 2: Market Impact - The approval of the new veterinary drug certificate will enrich the company's poultry vaccine product line and improve its competitive edge in the market [1]

Core Viewpoint - The announcement indicates that the company's wholly-owned subsidiary, Luoyang Huizhong Biotechnology Co., Ltd., has received a new veterinary drug registration certificate for a trivalent inactivated vaccine targeting three chicken diseases, enhancing the company's product portfolio and competitiveness in the poultry vaccine market [1] Group 1 - The vaccine is designed to prevent three diseases: Newcastle disease, avian influenza (H9 subtype), and infectious bursal disease [1] - The registration certificate was issued by the Ministry of Agriculture and Rural Affairs on January 12, 2026, marking a significant regulatory milestone for the product [1] - The vaccine is classified as a Category III new veterinary drug, indicating its potential impact on animal health and the poultry industry [1] Group 2 - The product still requires approval for veterinary drug product registration before it can be marketed, indicating further steps in the regulatory process [1] - This development enriches the company's poultry vaccine offerings, which is expected to enhance its competitive edge in the market [1]